• MedLumics’ oversubscribed financing round closes at EUR 18M to advance optically-guided real-time ablation catheter technology for the treatment of Atrial Fibrillation
  • MedTech veteran, Rich Ferrari, joins MedLumics’ Board of Directors as new Chairman

 

Madrid, Spain, [10 February 2021] – MedLumics, a privately held medical device company developing AblaView®, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round and has appointed Rich Ferrari as Chairman of the Board of Directors. MedLumics’ optical catheter displays lesion creation in real-time providing the physician with direct visual confirmation of conduction tissue denaturation.

 

Kurma Partners joined the round which includes and was initially led by Asabys Partners, along with new investors, VI Partners Swiss Innovation and CDTI Innvierte Economía, and existing investors Andera Partners, Caixa Capital Risc and Innogest Capital II. Having achieved pre-clinical feasibility in 2020, these proceeds will now enable MedLumics to initiate first in-human regulatory clinical studies and automate scalable product manufacturing.

 

Concurrent with the financing, Medlumics welcomes renowned venture capital investor Rich Ferrari as new Chairman of the Board of Directors. Mr. Ferrari brings to the team his wealth of experience in medical device innovation and commercialization as a successful CEO of two publicly traded medical technology companies and as co-founder and Managing Director of De Novo Ventures. Current Chairman Olivier Litzka of Andera Partners will assume the role of Vice Chairman.

 

Commenting on the news, James Greene, CEO of MedLumics, said: “We are very pleased to have received funding from such a strong investment syndicate and I am delighted to welcome Rich Ferrari as Chairman to our Board. We are honoured to have attracted someone of his calibre and look forward to benefiting from his impressive experience to support MedLumics as we progress through our development towards market entry. I would like to give heartfelt thanks to Olivier Litzka for his advice and guidance these past years and we are very grateful for his continued support as Vice Chairman of the Board.”

 

Olivier Litzka, Partner at Andera Partners, commented: “We have seen an intensive and exciting period between 2017 and 2020, in which Medlumics has masterminded technically one of the most difficult to accomplish challenges in the electrophysiology lab by delivering a catheter which is capable of performing real-time lesion assessments during AF ablation.  Following this achievement, we are in a favourable position to have attracted Rich Ferrari, an accomplished medtech entrepreneur, executive, board member and investor, and we look forward to moving towards clinical proof of concept under his Chairmanship.”

Rich Ferrari, newly appointed Chairman, added: “I am very excited to be joining such a competent team and board of directors. The Medlumics technology has the potential to greatly enhance clinical outcomes by providing real time feedback on constant contact of the ablation and visual display of the depth and conductivity of the tissue.”

 

Peter Neubeck, Partner at Kurma Partners, said: “We are excited to work with MedLumics in developing a truly innovative technology, a potential game changer in the interventional treatment of Atrial Fibrillation, a multi-billion-euro market opportunity. Patient outcomes will be dramatically impacted by the ability of clinicians to follow in real time the progression of ablations and their quality. We are happy to be joining this talented team and our syndicate partners, in supporting MedLumics’ evolution into a successful international business.”

 

Atrial Fibrillation is the most common type of cardiac arrhythmia, currently affecting an estimated 33 million people worldwide. AF recurrence remains high with more than 20% of patients undergoing repeat ablation within one year of initial treatment. Addressing an unmet clinical need, AblaView is the first imaging system to directly assess lesion creation, allowing the operator to confidently ascertain the stability of the contact and the positioning of the catheter on the atrial wall. Recent preclinical studies have been successful in demonstrating reliable monitoring of the continuity and transmurality of the cardiac tissue ablation in real-time.

 

Rich Ferrari has over 35 years in the healthcare industry, with a demonstrated history of working in the venture capital and private equity industry. Prior to founding De Novo Ventures in 2000, Rich was a successful CEO of medical technology companies, CardioThoracic Systems (CTS) and Cardiovascular Imaging Systems, both of which he took public. Rich remains very active as Executive Chairman of De Novo Ventures and mentors many first time CEOs. He also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, as well as a board member for the Stanford Coulter Foundation for Translational Medicine. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.

Share on :

More news

AVERTISSEMENT - CAUTION

TEMPS DE LECTURE : 2 MINUTES

READING TIME: 2 MINUTES


TENTATIVE DE FRAUDE : À LIRE ATTENTIVEMENT
ATTEMPTED FRAUD: READ IT CAREFULLY (English below)

ANDERA PARTNERS attire votre attention sur les tentatives de fraudes avec usurpation d’identité qui sévissent actuellement. Les techniques de phishing (ou hameçonnage) évoluent en permanence et sont de plus en plus sophistiquées.

Ces pratiques frauduleuses qui touchent ANDERA PARTNERS, invitent les particuliers à investir dans des comptes à terme et autres produits d’épargne fictifs sous l’identité d’ ANDERA PARTNERS (Andera Co-Invest notamment), et celles de ses collaborateurs et membres des organes de direction, via une adresse fictive et des appels téléphoniques.

Nous vous invitons à la plus grande vigilance si vous receviez ce type de sollicitations. ANDERA PARTNERS ne propose pas de compte à terme et n’a recours à aucun démarchage auprès du public, ni par téléphone ni par courriel.

Les fraudeurs ne manquent pas d'imagination pour piéger leurs victimes. Leurs actions visent à récupérer à leur insu et de manière indue des données financières, en incitant leurs victimes à réaliser des transactions dématérialisées.
En cas de doute, pour vous protéger et protéger ANDERA PARTNERS, nous vous invitons à :

*   Vous méfier des demandes inattendues, même si elles semblent provenir de dirigeants ou membre d’organes de direction d’ANDERA PARTNERS ;

*   Vérifier l’adresse de l’expéditeur. Les adresses électroniques des collaborateurs d’ANDERA PARTNERS utilisent un seul et même format : initialeduprénom.nom@anderapartners.com. Les adresses globales sont ainsi libellées : nomduservice@anderapartners.com ;

*   Ne jamais cliquer sur un lien vous demandant de partager des informations sensibles et ne jamais répondre à des demandes financières en ligne ;

*   Signaler tout message suspect qui vous demande une action immédiate.

La priorité d'ANDERA PARTNERS est de protéger ses clients et ses activités contre la fraude.
Si vous êtes victime d'une tentative d’escroquerie, veuillez contacter les relations investisseurs à l’adresse suivante : ri@anderapartners.com

Liens utiles :

LISTE NOIRE DES SOCIÉTÉS FRAUDULEUSES ÉTABLIE PAR L’AMF (AUTORITÉ DES MARCHÉS FINANCIERS) : https://www.amf-france.org/fr/espace-epargnants/proteger-son-epargne/listes-noires-et-mises-en-garde

VICTIME D'UNE ARNAQUE : COMMENT DÉPOSER UNE PLAINTE ? | AMF (AMF-FRANCE.ORG) : https://www.amf-france.org/fr/espace-epargnants/savoir-bien-investir/conseils-pratiques/en-cas-de-problemes/victime-dune-arnaque

_____________________________________________________________

ANDERA PARTNERS would like to draw your attention to fraud attempts involving identity theft that are currently rife. Phishing techniques are constantly evolving and becoming increasingly sophisticated.

These fraudulent practices, which affect ANDERA PARTNERS, invite individuals to invest in term accounts and other fictitious savings products under the identity of ANDERA PARTNERS (Andera Co-Invest in particular), and those of its employees and members of the management company, via a fictitious address and telephone calls.

Please be extremely vigilant if you receive this type of solicitation. ANDERA PARTNERS does not offer term accounts and does not canvass the public by telephone or e-mail.

Fraudsters do not lack imagination to trap their victims. Their actions are aimed at unknowingly and improperly recovering financial data, by encouraging their victims to carry out dematerialised transactions.
If in doubt, to protect yourself and ANDERA PARTNERS, we invite you to :

* Be wary of unexpected requests, even if they appear to come from ANDERA PARTNERS managers or members of management bodies;

* Check the sender's address. The e-mail addresses of ANDERA PARTNERS employees use a single format: initialeduprénom.nom@anderapartners.com. Global addresses are written as follows: nomduservice@anderapartners.com ;

* Never click on a link asking you to share confidential information and never respond to online financial requests;

* Report any suspicious message that asks you to take immediate action.

ANDERA PARTNERS' priority is to protect its customers and its business against fraud.
If you are the victim of a fraud attempt, please contact Investor Relations at the following address: ri@anderapartners.com

This will close in 0 seconds